Neoplasms

All Conditions

Symptoms and General Pathology

Gland and Hormone Related Diseases

Digestive System Diseases

Nervous System Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Rare Diseases

Carcinoma

Recurrence

Thyroid Neoplasms

Thyroid Diseases

Liver Neoplasms

Glioblastoma

Pheochromocytoma

Head and Neck Neoplasms

Glioma

Sarcoma

Brain Neoplasms

Mesothelioma

Mesothelioma, Malignant

Thyroid Cancer, Papillary

Central Nervous System Neoplasms

Medulloblastoma

Thyroid Carcinoma, Anaplastic

Nervous System Neoplasms

Astrocytoma

Adrenocortical Carcinoma

Ependymoma

Carcinoma, Medullary

Oligodendroglioma

Gliosarcoma

Adenocarcinoma, Follicular

Glioma, Subependymal

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Connective and Soft Tissue

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Adenoma

Neoplasms, Mesothelial

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Pleural Neoplasms

Lung Diseases

Respiratory Tract Diseases

Paraganglioma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Adenocarcinoma

Adrenal Cortex Neoplasms

Adrenal Gland Neoplasms

Endocrine Gland Neoplasms

Adrenal Cortex Diseases

Adrenal Gland Diseases

Endocrine System Diseases

Primary Liver Cancer

Soft Tissue Sarcoma

Malignant Mesothelioma

Papillary Thyroid Carcinoma

Brain Tumor, Adult

Anaplastic Thyroid Cancer

Brain Tumor, Childhood

Anaplastic Astrocytoma

Thyroid Cancer, Medullary

Anaplastic Oligodendroglioma

Diffuse Astrocytoma

Childhood Brain Stem Glioma

Thyroid Cancer, Follicular

Pilocytic Astrocytoma

Medulloblastoma, Childhood

Anaplastic Ependymoma

Cerebellar Astrocytoma, Childhood

Cerebral Astrocytoma, Childhood

Subependymoma

Myxopapillary Ependymoma

Paragangliomas 1

Neuroendocrine Tumor

Neuroepithelioma

Bone Density Conservation Agents

Antineoplastic Agents

All Drugs and Chemicals

Anticoagulants

Hematinics

Anti-Infective Agents

Other Dietary Supplements

Tamoxifen

Doxorubicin

Liposomal doxorubicin

Cisplatin

Citric Acid

Sodium Citrate

Liver Extracts

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Estrogens

Estrogen Antagonists

Estrogen Receptor Antagonists

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Estrogen Receptor Modulators

Selective Estrogen Receptor Modulators

Citrate

cisplatin

doxorubicin hydrochloride

tamoxifen citrate

conventional surgery

radiation therapy

Stan Z. Gertler, MD, FRCPC

RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone therapy using tamoxifen may fight cancer by blocking the uptake of estrogen. Combining tamoxifen with chemotherapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving cisplatin and doxorubicin together with tamoxifen works in treating patients with solid tumors.

OBJECTIVES:

* Determine the feasibility and efficacy of cisplatin, doxorubicin, and tamoxifen (CAT) in patients with soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer.
* Determine the toxicity of this regimen in these patients.

OUTLINE: Patients receive cisplatin IV over 1-2 hours followed immediately by doxorubicin IV over 15-30 minutes on days 1-3 and oral tamoxifen twice daily on days 4-17. Treatment continues every 3 weeks in the absence of the total cumulative doxorubicin dose reaching at least 500 mg/m2, disease progression, or unacceptable toxicity. Patients who achieve partial remission (PR) undergo local surgery or radiotherapy, if feasible, to convert PR to complete remission.

Patients are followed every 2 months for 1 year and then every 3 months for 2 years.

PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study.

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies

Ottawa Regional Cancer Centre

Carcinoma, Hepatocellular

Rhabdoid Tumor

Hepatoblastoma

Embryonal Sarcoma

Morgan Paul, BSN

Daniel Pieratt, MPA

Morgan L Paul, BSN

Rakesh Sindhi, MD

The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.

Pediatric liver cancers are rare, affecting at times no more than 1 in one million population. Understanding the molecular basis of these cancers is important in order to develop more accurate diagnoses and more effective treatments. Current classifications of these cancers are based on how these cancers look on diagnostic studies such as radiologic imaging or under the microscope. Such a classification system does not explain why a particular cancer has a different outcome from what is considered "usual" for that particular cancer. Nor does such a classification system explain why two different classes of cancers behave the same way. Understanding the genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.

To achieve these goals, large numbers of such cancer patients or affected tissue must be collected. This is not possible in any single institution, or any single country. The current project will collect biological samples such as residual tumor tissue, saliva, or blood from affected patients and their biological parents and families, along with clinical information about the cancer. These biological samples will be used to study the genes and how these genes work in tumor tissue and in non-tumor tissue. The results of this study will permit childhood liver cancers to be categorized on the basis of common defects in genes and their function.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors	NCT00002608	Adrenocortical ... Brain and Centr... Head and Neck C... Liver Cancer Malignant Mesot... Pheochromocytom... Sarcoma	cisplatin doxorubicin hyd... tamoxifen citra... conventional su... radiation thera...	- 65 Years	National Cancer Institute (NCI)
Molecular Basis of Pediatric Liver Cancer	NCT03959800	Childhood Liver... Liver Malignant... Embryonal Sarco... Hepatoblastoma Hepatocellular ... Rhabdoid Tumor ...		0 Years - 99 Years	University of Pittsburgh

Spots Global Cancer Trial Database for childhood liver cancer